Organization

Oklahoma City, OK

6 abstracts

Abstract
Costs and access barriers to ondansetron: A national analysis of Medicare part D and Medicare Advantage plans.
Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Dallas, TX, UT Southwestern Medical Center,
Abstract
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Stephenson Cancer Center University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, OK,
Abstract
Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience.
Org: Veterans Affairs Medical Center, Oklahoma City, OK, Oklahoma City VA Health Care System,
Abstract
Beyond transportation: Financial hardship, food insecurity, and care access barriers among US cancer survivors with transportation barriers to care.
Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, American Cancer Society, Atlanta, GA, Case Comprehensive Cancer Center,
Abstract
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.
Org: Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France, Institut Gustave Roussy, Villejuif, France, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,